US EditionPublished • loading... • Updated
Bayer proposes US$10.25 billion plan for all Roundup cancer cases
Bayer aims to resolve about 65,000 U.S. claims alleging Roundup caused non-Hodgkin lymphoma with a $7.25 billion settlement, reducing litigation risks amid pending Supreme Court review.
- On Tuesday, Bayer's Monsanto unit filed a proposed $7.25 billion nationwide class settlement in St. Louis Circuit Court to resolve current and future Non-Hodgkin lymphoma claims.
- The move follows the U.S. Supreme Court agreeing to hear Bayer's failure-to-warn appeal, with oral arguments set for April 27, as Bayer argues federal law preempts state failure-to-warn suits under EPA-approved labels.
- The deal creates a long-term claims program with capped annual payments over 17 to 21 years, distributing compensation via a tiered grid with average awards up to $165,000 and maximum awards of $198,000.
- Bayer postponed publication of its 2025 results and 2026 guidance to March 4 as it reflected the agreements, warning provisions will rise to 11.8 billion euros and shares jumped after the announcement.
- A favorable Supreme Court ruling could wipe out several large verdicts on appeal and sharply limit Bayer's liability, while approximately 65,000 plaintiffs still have pending claims after prior $10 billion payouts.
Insights by Ground AI
Podcasts & Opinions
139 Articles
139 Articles
At $7.25 billion, Bayer wants to finally settle the case against Roundup. Shareholders are breathing up.
Bayer Agrees to $7.25B Roundup Settlement Plan
Agrochemical maker Bayer and attorneys for cancer patients announced a proposed $7.25 billion settlement Tuesday to resolve thousands of US lawsuits alleging the company failed to warn people that its popular weedkiller Roundup could cause cancer. The proposed settlement comes as the US Supreme Court is preparing to hear...
·Miami, United States
Read Full Article
Coverage Details
Total News Sources139
Leaning Left18Leaning Right15Center79Last UpdatedBias Distribution71% Center
Bias Distribution
- 71% of the sources are Center
71% Center
L 16%
C 71%
13%
Factuality
To view factuality data please Upgrade to Premium
